First Results of the NeoALTTO (BIG 01-06/EGF 106903) Neoadjuvant Study of Lapatinib, Trastuzumab or the Combination and Paclitaxel for Women with HER2-Positive Primary Breast Cancer


First Results of the NeoALTTO (BIG 01-06/EGF 106903) Neoadjuvant Study of Lapatinib, Trastuzumab or the Combination and Paclitaxel for Women with HER2-Positive Primary Breast Cancer
Slides from a presentation at SABCS 2010 and comments from a recent interview with Eric P Winer, MD (12/11/10)

Baselga J et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER 2-positive primary breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S3-3.

Dr Winer is Thompson Investigator in Breast Cancer Research and Chief of the Division of Women’s Cancers at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.